Nanobiotix shares fall 13% in one week and give back most of their rebound
The Parisian oncology nanomedicine biotech slips at midday, in a Paris market trending lower. This decline extends a difficult week and places the stock in the lower half of the broader index ranking.
A weekly decline that brings the stock back below all its moving averages
The stock loses 2.7% to €25.24, after a 13.09% drop over seven days that erases much of the sharp recovery seen in November.
The session takes place as the SBF 120 falls 1.22% to 6,037.76 points and the CAC 40 drops 1.16%, in a context of strong pressure on global technology stocks. Nanobiotix ranks near the bottom of the index, without being among the largest decliners.
Sanofi (+1.66%) and Eurofins Scientific (-0.26%), which operate in healthcare, show more resilient performance.
The share price is now below its three moving averages: the MM20 at €27.46 is 8.08% above, the MM50 at €26.07 is 3.18% above, and the MM200 at €29.90 is 15.59% above. The RSI at 46 remains neutral: the weekly decline has not exhausted the stock.
Cash of €110.9 million announced in September, funding through 2029
When publishing its first-half 2026 results on September 24, the company indicated that its cash of €110.9 million would allow it to finance its operations until 2029, and that it did not see any substantial doubt about its ability to continue its activity over the next twelve months. This financing horizon fits within the model of a biotech developing NBTXR3 (JNJ-1900), a radioenhancer combined with radiotherapy, in partnership with Johnson & Johnson.
The stock is listed in Paris as an ordinary share eligible for the PEA, and on the Nasdaq as ADSs, at a ratio of one ADS per share: the two lines most often move on the same day.
After a one-month gain of 33.9%, the weekly decline brought the stock back toward its mid-month level, above the support at €18.85 and below the resistance at €30.36.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
SectorPharmacie et biotechnologies›Biotechnologies
Context
Period
Period: S1 2026
Key reported figures
Revenue: 3,6 millions d'euros
Quarterly revenue: 3,6 millions d'euros
Net income: -34,3 millions d'euros
Guidance from the release
« la Société estime qu'elle disposera des liquidités suffisantes pour faire face à ses obligations financières […] pendant au moins les 12 prochains mois […] pas de doute substantiel quant à la capacité de la Société à poursuivre son activité » ; CP du 24/09 : trésorerie de 110,9 M€ « permettront de financer ses opérations jusqu'en 2029 »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.